Randomised Phase II Study comparing, as first-line chemotherapy, single-agent Oral Vinorelbine administered with two different schedules in patients with Advanced Breast Cancer
Randomised Phase II Study comparing, as first-line chemotherapy, single-agent Oral Vinorelbine administered with two different schedules in patients with Advanced Breast Cancer
TEMPOBREAST 01
Randomised Phase II Study comparing, as first-line chemotherapy, single-agent Oral Vinorelbine administered with two different schedules in patients with Advanced Breast Cancer
Statut
Status :
Terminé
Type d'étude
Phase II
Age Min.
18
Ans
Age Max.
-
Genre
Femme
Aire thérapeutique :
Oncologie
Maladie :
Cancer du sein
Traitement :
Vinorelbine (Navelbine® Oral)
Phase :
Phase II
Date de début de l'étude :
03 Août 2015
End date :
28 Septembre 2020
Identifiant de l'essai :
PM 0259 CA 233 B0
Identifiant EudraCT/CTIS :
2014-003860-19
Envoyer par email